¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019 ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ Çмú´ëȸ : 2019-05-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019 ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ Çмú´ëȸ : 2019-05-29
±³À°ÀÏÀÚ : 2019-05-29
±³À°Àå¼Ò : ´õÄÉÀÌÈ£ÅÚ¼­¿ï ÄÁº¥¼Ç¼¾ÅÍ  
±³À°ÁÖÁ¦ : 2019 ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : À¯ÀüºÐÀÚÁø´ÜÇÐȸ  
´ã´çÀÚ : À̼Ҷó
¿¬¶ôó : 02-795-9914  
À̸ÞÀÏ : kscp1@kams.or.kr      
±³À°Á¾·ù : Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 17 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í Á¤È¸¿ø-8¸¸¿ø, Àü°øÀÇ-8¸¸¿ø, Àü¹®ÀÇ-12¸¸¿ø,»ê¾÷°è 15¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 08:30~09:00 2019 À¯ÀüÀÚ°Ë»ç±â°ü ÁúÆò°¡ ü°è ¹× ½É»ç ÀϹݻçÇ×  ÀÌ¿µ°æ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 09:00~09:30 Àü»ê ½Ã½ºÅÛÀ» ÀÌ¿ëÇÑ ÇöÀå ½Ç»ç  À¯Á¾ÇÏ(±¹¹Î°Ç°­º¸Çè Àϻ꺴¿ø) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 09:30~09:50 ½É»çÁ¡°ËÇ¥ ¼³¸í – °Ë»ç½Ç ¿î¿µ  ¾ÈÁ¤¿­(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 09:50~10:10 ½É»çÁ¡°ËÇ¥ ¼³¸í – ºÐÀÚÀ¯Àü  ÀåÀÚÇö(³ì½ÊÀÚÀÇ·áÀç´Ü) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 10:10~10:30 ½É»çÁ¡°ËÇ¥ ¼³¸í – ¼¼Æ÷À¯Àü  ÀÌÁø°æ(Çѱ¹¿øÀÚ·ÂÀÇÇпø) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 09:00~09:30 Screening risk individuals in health check up  È²±Ý·Ï(¼­¿ïÀÇ°úÇבּ¸¼Ò) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 09:30~10:00 Personal identification and chimerism assay by NGS  ±èÁöÀº(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 10:00~10:30 NGS-based HLA typing  ¹ÚÀ±Èñ(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-29 ±Ý°­È¦A 09:00~09:30 Culture & slide preparation  ¼ÕÁ¤¿Á(¼­¿ï¼º¸ðº´¿ø) 
±³À°½Ã°£ 05-29 ±Ý°­È¦A 09:30~10:00 Reading & interpretation  ¼³Ã¢¾È(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 05-29 ±Ý°­È¦A 10:00~10:30 Point issues in past proficiency test  ±è°æÈñ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 11:00~12:00 Molecular drivers of inherited hematopoietic malignancies  Mark D. Ewalt(University of Colorado School of Medicine) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 12:00~13:10 Effectively manage your transplant patients with standardized & clinically validated results   ÁöÇö¼÷(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 12:00~12:30 Clinical genetic testing using NGS: Lessons learned and future direction  Ã¤Á¾Èñ(¼­¿ïÀÇ´ë Èñ±ÍÁúȯ¼¾ÅÍ) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 12:30~13:10 High throughput data analysis using dragen system  Tan, Yue Ying(Sr Bioinformatics Specialist, Illumina) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 13:10~13:40 Low level somatic mosaicism in neurologic disorders  °­ÈÆö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 13:40~14:10 The scope of hereditary tumor syndrome is expanding in the NGS era  ÀÌ¿ìâ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 14:10~14:40 Precision genomics and treatment in neuromuscular disorders  ÀÌÁ¤È¯(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 05-29 ±Ý°­È¦A 13:10~13:40 ±¹³» À¯Àü»ó´ãŬ¸®´Ð ÇöȲ  À¯Á¾ÇÏ(±¹¹Î°Ç°­º¸Çè Àϻ꺴¿ø) 
±³À°½Ã°£ 05-29 ±Ý°­È¦A 13:40~14:10 À¯Àü »ó´ã Ŭ¸®´Ð ½ÃÀÛÇϱ⠠±èµµÈÆ(°è¸íÀÇ´ë) 
±³À°½Ã°£ 05-29 ±Ý°­È¦A 14:10~14:40 À¯Àü »ó´ã Ŭ¸®´Ð ¿î¿µ A, B, C  ½Å°æÈ­(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 13:10~13:40 Data analysis of DNA-Seq  ±è¼±¿µ(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 13:40~14:10 Data analysis of RNA-Seq  ÀÌÁØÇü(Àü³²ÀÇ´ë) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 14:10~14:40 Deep learning for genomics  ¼º¹®¿ì(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 15:10~15:40 Epilepsy-related disorders  ÀÓº´Âù(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 15:40~16:10 NGS-guided precision medicine in inherited eye disorders  ÇÑÁø¿ì(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-29 ±×·£µåº¼·ëB 16:10~16:40 Immune deficiency  ±è¿¹Áø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 05-29 ±Ý°­È¦A 15:10~15:40 Urea cycle disorders and hyperammonemia  ÀÌ°æÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-29 ±Ý°­È¦A 15:40~16:10 Disorders of carnitine cycle and fatty acid oxidation disorders  ±è¼¼¸²(³ì½ÊÀÚÀÇ·áÀç´Ü) 
±³À°½Ã°£ 05-29 ±Ý°­È¦A 16:10~16:40 Galactosemia  ¾È¼±Çö(¼­¿ïÀÇ°úÇבּ¸¼Ò) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 15:10~15:40 À¯ÀüÀÚÀç¹è¿­ÀÇ Á¤¼ºÀû °ËÃâ  ¼­ÀÚ¿µ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 15:40~16:10 À¯ÀüÀÚÀç¹è¿­ÀÇ Á¤·®Àû °ËÃâ  Á¶¿µ¿í(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 05-29 Å©¸®½ºÅ»º¼·ë 16:10~16:40 ¿°±â¼­¿­ºÐ¼®À» ÀÌ¿ëÇÑ µ¹¿¬º¯ÀÌ °ËÃâ  ±è¹Ì¿µ(ÇѸ²ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019 ´ëÇÑÁø´ÜÀ¯ÀüÇÐȸ Çмú´ëȸ : 2019-05-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼øõÇâ´ëÇб³Ãµ¾Èº´¿ø ½Å»ý¾Æ¼Ò»ý¼ú : 2019-05-29
´ÙÀ½±Û Ãæ³²´ëÇб³º´¿ø Multidiciplinary approach to Developmental Epileptic Encephalopathy : 2019-05-29
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20649 ´ëÀü °ø°ø±â°ü ÀçÁ÷ÀÇ»ç Ãá°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-05-23 0 8 2024-05-10
20648 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦1Â÷¿¬¼ö±³À°(ºóÇ÷ ¹× ÃâÇ÷ Áúȯ, ÀÏÂ÷ ÀÇ·á±â°ü¿¡¼­ÀÇ °ü¸®) : 2024-05-23 0 16 2024-05-10
20647 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀüÃæûÁöȸ - Á¦2Â÷ ¿ù·ÊÁý´ãȸ : 2024-05-23 0 17 2024-05-10
20646 Á¦ÁÖ ´ëÇÑÇǺΰúÇÐȸ Á¦ÁÖÁöºÎȸ 2024³â Á¦1Â÷ Áý´ãȸ : 2024-05-22 0 9 2024-05-10
20645 ´ë±¸ ´ëÇѾȰúÇÐȸ ´ë±¸°æºÏÁöȸ ¿¬¼ö±³À°-¹é³»Àå ¹× Àü¾ÈºÎ ÃֽŠÁö°ß : 2024-05-21 0 8 2024-05-10
20644 ¼­¿ï ¾çõ±¸ÀÇ»çȸ Ãá°è¿¬¼ö±³À°(Á¦2Çü ´ç´¢º´°ú ¸¸¼º ½ÅÀ庴, ÀÎÁöÀå¾Ö, ¸ÞŸ¹ö½º¿Í ÀÇ·á Çõ¸í) : 2024-05-21 0 13 2024-05-10
20643 ÃæºÏ 2024 Á¦Ãµ½ÃÀÇ»çȸ Ãá°è ¿¬¼ö°­Á : 2024-05-21 0 5 2024-05-10
20642 ºÎ»ê Á¦28Â÷ ¾Æ½Ã¾Æ-¿À¼¼¾Æ´Ï¾Æ »êºÎÀΰú¿¬¸Í Çмú´ëȸ (AOFOG 2024) (4ÀÏÂ÷) : 2024-05-20 0 16 2024-05-10
20641 ¼­¿ï ´ëÇÑÀÓ»ó³ëÀÎÀÇÇÐȸ 2024 Ãá°è ³ëÀÎÀÇÇÐ ¿¬¼ö°­Á : 2024-05-19 0 22 2024-05-10
20640 ¼­¿ï ´ëÇÑÀçÈ°ÀÇÇаúÀÇ»çȸ Stanley Lam ¿öÅ©¼¥ : 2024-05-19 0 33 2024-05-10
20639 ¼­¿ï Á¦40ȸ ´ëÇѳëÀÎÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 22 2024-05-10
20638 ¼­¿ï ´ëÇÑÁ¾¾ç¿Ü°úÇÐȸ 2024³âµµ ¿¬¼ö°­Á : 2024-05-18 0 15 2024-05-10
20637 ÀÎõ 2024³âµµ Á¦47Â÷ ´ëÇѺ¹ºÎ¿µ»óÀÇÇÐȸ Çмú´ëȸ(2ÀÏÂ÷) : 2024-05-18 0 7 2024-05-10
20636 Àü³² 2024 Á¦2Â÷ ´ëÇѾȰúÀÇ»çȸ ½ÉÆ÷Áö¿ò : 2024-05-18 0 3 2024-05-10
20635 ¼­¿ï ´ëÇÑÇǺκ´¸®ÇÐȸ Á¦22ȸ ÇǺκ´¸® ½ÉÆ÷Áö¿ò : 2024-05-18 0 33 2024-05-10
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷